Stocks of Aurobindo Pharma gained nearly 3 per cent today as the company received final nod from the US health regulator to make and market generic anti-epileptic Phenytoin Sodium capsules in America.
The scrip settled 2.87 per cent higher at Rs 1,313.45 on the BSE. In intraday, it climbed 3.45 per cent to Rs 1,321.
On the NSE, shares of Aurobindo rose by 2.91 per cent to close at Rs 1,314.
"The company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market extended Phenytoin Sodium capsules USP, 100mg," Aurobindo Pharma had said in a statement yesterday.
The approved abbreviated new drug application (ANDA) is for the generic version of Pfizer Inc Parke-Davis Division's Dilantin capsules.
The product has an estimated market size of USD 125 million for 12 months ended April 2015, Aurobindo Pharma said quoting IMS data.
The anti-epileptic product is indicated for control of seizures and prevention and treatment of seizures occurring during or following neurosurgery, it added.
